First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2027 revenue reaching $1.3B — +11.9% growth in a single year.
What Moves the Stock
1Translarna regulatory decisions - EMA annual renewal of conditional approval (typically Q3-Q4), potential FDA approval attempts, and patent expiration timeline in EU (2025-2027 depending on jurisdiction)
2Clinical trial readouts for pipeline assets - PTC518 Phase 2 data in Huntington's disease, PTC-AADC gene therapy updates, sepiapterin reductase deficiency program milestones
3Upstaza commercial uptake - quarterly patient starts, reimbursement approvals in new markets (US filing potential), and manufacturing capacity expansion
4Business development activity - licensing deals, asset acquisitions to diversify beyond Duchenne franchise, or potential sale of non-core assets
5Quarterly revenue performance vs consensus - particularly Translarna geographic mix and Upstaza patient additions
6Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy - approximately 60-65% of revenue, sold in EU, Latin America, and other ex-US markets under conditional approval
7Upstaza (eladocagene exuparvovec) gene therapy for AADC deficiency - launched 2022 in EU, one-time $3M+ treatment, early revenue ramp
8Tegsedi and Waylivra (licensed from Ionis) for rare metabolic disorders - approximately 15-20% of revenue, declining contribution
growth/speculative - Attracts biotech-focused growth investors and event-driven hedge funds playing clinical catalysts and regulatory binary…
Rising rates create moderate headwinds through two channels: (1) Higher discount rates compress NPV of long-duration pipeline assets…
Watch on earnings: Translarna quarterly revenue trend and patient discontinuation rates - early warning of patent cliff acceleration or reimbursement pressure, EMA conditional approval renewal decisions (annual Q3-Q4 timing) - binary catalyst for 60% of revenue base, Upstaza patient start cadence and geographic reimbursement expansion - tracking toward $150-200M peak sales potential.
One Sentence Summary:
PTC Therapeutics: the story is balanced — translarna regulatory decisions - ema annual renewal of conditional approval (typically q3-q4), potential fda approval attempts.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.